Curis stock fell 5.07 percent as targets reached USD 65

Published on 10/07/2026 at 04:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Analysts list a Strong Buy consensus for Curis with a USD 42.6667 average target on September 17, 2026. The company is advancing emavusertib toward clinical data.

CRIS, US2312694084, Illustration mit AI erstellt.

Curis stock (ISIN US2312694084) was last at USD 0.75 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 5.07 percent from USD 0.79. The move leaves the biotechnology company close to its 52-week low while analyst targets remain far above the market quote.

Targets dwarf the market quote

According to Investing.com on September 17, 2026, the published consensus carries a Strong Buy label. The rating table shows four analysts, while the 12-month target data show an average of USD 42.6667, a low of USD 20 and a high of USD 65.

Against the October 6 quote of USD 0.75, the average target is 5,588.9 percent higher. That comparison reflects the gap between a clinical-stage biotechnology valuation and the market's immediate assessment, rather than a guaranteed return.

Emavusertib drives the story

Curis describes itself as a biotechnology company developing cancer therapeutics, with emavusertib as its central clinical program. The oral IRAK4 and FLT3 inhibitor is being studied across blood cancers, including lymphoma and leukemia indications.

The company reported on its investor-relations page that it dosed the first five patients in the TakeAim CLL study on July 30, 2026. The same page identifies the August 13, 2026 pricing of a USD 5.6 million public offering, adding financing to the clinical execution story.

Stock trades near yearly low

Curis shares covered USD 0.73 to USD 0.77 during the October 6 session, with volume of 182,514 shares. The 52-week range of USD 0.72 to USD 34.00 places the latest quote USD 0.03 above the low and USD 33.25 below the high.

Market capitalization stood at USD 1.5 million on October 6, 2026. Investing.com lists November 11, 2026 as the next earnings date, giving investors a dated checkpoint for the pipeline and financing picture.